Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6001 injection plus toripalimab in advanced melanoma
CTR20230746Phase 2Active
- Sponsor
- Condat Biopharmaceutical
- Start
- Mar 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KD6001 in melanoma, sponsored by Condat Biopharmaceutical. Started Mar 2023; status: active.
02
Drugs
KD6001
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20230746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230746.